Cargando…

Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity

The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Pembroke, Tom, Rees, Ian, Gallagher, Kathleen, Jones, Emma, Mizen, Paul, Navruzov, Timur, Freedman, Andrew, Fielding, Ceri, Humphreys, Ian R, Wang, Eddie C Y, Gallimore, Awen M, Godkin, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781703/
https://www.ncbi.nlm.nih.gov/pubmed/22653709
http://dx.doi.org/10.1002/eji.201142072
_version_ 1782285468660924416
author Pembroke, Tom
Rees, Ian
Gallagher, Kathleen
Jones, Emma
Mizen, Paul
Navruzov, Timur
Freedman, Andrew
Fielding, Ceri
Humphreys, Ian R
Wang, Eddie C Y
Gallimore, Awen M
Godkin, Andrew
author_facet Pembroke, Tom
Rees, Ian
Gallagher, Kathleen
Jones, Emma
Mizen, Paul
Navruzov, Timur
Freedman, Andrew
Fielding, Ceri
Humphreys, Ian R
Wang, Eddie C Y
Gallimore, Awen M
Godkin, Andrew
author_sort Pembroke, Tom
collection PubMed
description The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measured repeatedly in a cohort of chronically HCV-infected subjects (n = 33) receiving IFN-α. Rapid control of virus indicated by an increased calculated rate of virus clearance, occurred in those subjects demonstrating absent/minimal T-cell responses (p < 0.0006). Surprisingly, in subjects who demonstrated the most robust T-cell responses (and reduced serum IL-10), there was actually a reduced rate of early virus clearance. A subsequent analysis of NK-cell function in available subjects (n = 8) revealed an inverse correlation between pretreatment NK-cell expression of NKp46 and the potential to upregulate cytotoxic function on exposure to IFN-α (p < 0.004), as well as the subsequent measured rate of viral clearance (p = 0.045). Thus, the CD4(+) T-cell response during IFN-α treatment appears to be shaped by the rate of innate virus suppression. These data suggest that individuals who respond most effectively to immune intervention may be most in need of subsequent vaccination to prevent reinfection.
format Online
Article
Text
id pubmed-3781703
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-37817032013-09-25 Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity Pembroke, Tom Rees, Ian Gallagher, Kathleen Jones, Emma Mizen, Paul Navruzov, Timur Freedman, Andrew Fielding, Ceri Humphreys, Ian R Wang, Eddie C Y Gallimore, Awen M Godkin, Andrew Eur J Immunol Immunity to Infection The ability to control HCV with IFN-α-based treatments provides an opportunity in humans to study how the rate of viral clearance in vivo impinges on the development of antiviral responses. Ex vivo (IFN-γ-producing) and cultured antiviral CD4(+) T cells, serum cytokines, and viral loads were measured repeatedly in a cohort of chronically HCV-infected subjects (n = 33) receiving IFN-α. Rapid control of virus indicated by an increased calculated rate of virus clearance, occurred in those subjects demonstrating absent/minimal T-cell responses (p < 0.0006). Surprisingly, in subjects who demonstrated the most robust T-cell responses (and reduced serum IL-10), there was actually a reduced rate of early virus clearance. A subsequent analysis of NK-cell function in available subjects (n = 8) revealed an inverse correlation between pretreatment NK-cell expression of NKp46 and the potential to upregulate cytotoxic function on exposure to IFN-α (p < 0.004), as well as the subsequent measured rate of viral clearance (p = 0.045). Thus, the CD4(+) T-cell response during IFN-α treatment appears to be shaped by the rate of innate virus suppression. These data suggest that individuals who respond most effectively to immune intervention may be most in need of subsequent vaccination to prevent reinfection. Blackwell Publishing Ltd 2012-09 2012-08-06 /pmc/articles/PMC3781703/ /pubmed/22653709 http://dx.doi.org/10.1002/eji.201142072 Text en © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Immunity to Infection
Pembroke, Tom
Rees, Ian
Gallagher, Kathleen
Jones, Emma
Mizen, Paul
Navruzov, Timur
Freedman, Andrew
Fielding, Ceri
Humphreys, Ian R
Wang, Eddie C Y
Gallimore, Awen M
Godkin, Andrew
Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title_full Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title_fullStr Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title_full_unstemmed Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title_short Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4(+) T-cell immunity
title_sort rapid early innate control of hepatitis c virus during ifn-α treatment compromises adaptive cd4(+) t-cell immunity
topic Immunity to Infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781703/
https://www.ncbi.nlm.nih.gov/pubmed/22653709
http://dx.doi.org/10.1002/eji.201142072
work_keys_str_mv AT pembroketom rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT reesian rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT gallagherkathleen rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT jonesemma rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT mizenpaul rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT navruzovtimur rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT freedmanandrew rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT fieldingceri rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT humphreysianr rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT wangeddiecy rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT gallimoreawenm rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity
AT godkinandrew rapidearlyinnatecontrolofhepatitiscvirusduringifnatreatmentcompromisesadaptivecd4tcellimmunity